Pulmonary Arterial Hypertension — Deal Benchmarks & Valuation
Market Analysis
Pulmonary Arterial Hypertension is one of the most actively transacted indications in cardiovascular licensing. Phase 2 deals for pulmonary arterial hypertension carry a median total deal value of $3.3B, with upfront payments ranging from $361M to $958M. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones.
Milestone structures for pulmonary arterial hypertension deals allocate $589M to development milestones, $749M to regulatory milestones, and $1.3B to commercial milestones. Royalty rates range from 9.6% to 19.3% at the base tier, with tiered escalation reaching 13.6%-23.3% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for pulmonary arterial hypertension licensing?
What royalty rates are standard for pulmonary arterial hypertension deals?
How are pulmonary arterial hypertension deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.